Skip to main content
Premium Trial:

Request an Annual Quote

Cellzome to Use BioSeek Platform in Inflammatory Diseases Research

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Tissue supply firm Asterand today said that its BioSeek subsidiary will provide its BioMap predictive human disease models to Cellzome for use in its inflammatory disease drug discovery projects.

The BioMap platform will be used to predict possible human clinical responses to small molecules identified by Cellzome using its own Kinobeads and Episphere screening and profiling technologies. The agreement is for two years.

"The BioMap platform will allow us to receive early insight into the human pharmacological and toxicological properties of our small molecules, enabling us to develop safer and more effective treatments for inflammation," Oliver Rausch, VP of Biology at Cambridge, UK-based Cellzome, said in a statement.

Financial and other terms of the agreement were not disclosed.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.